Volume | 319,080 |
|
|||||
News | - | ||||||
Day High | 4.91 | Low High |
|||||
Day Low | 4.60 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Sagiment Biosciences Inc | SGMT | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
4.79 | 4.60 | 4.91 | 4.82 | 4.70 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3,050 | 319,080 | $ 4.78 | $ 1,523,832 | - | 2.13 - 20.71 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:28:01 | 25 | $ 4.93 | USD |
Sagiment Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
103.03M | 21.38M | - | 2M | -27.88M | -1.30 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Sagiment Biosciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SGMT Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.71 | 5.20 | 4.44 | 4.81 | 570,630 | 0.11 | 2.34% |
1 Month | 4.00 | 5.20 | 3.88 | 4.47 | 488,392 | 0.82 | 20.50% |
3 Months | 6.21 | 7.41 | 3.83 | 4.85 | 704,552 | -1.39 | -22.38% |
6 Months | 3.72 | 20.71 | 3.5101 | 10.15 | 1,026,316 | 1.10 | 29.57% |
1 Year | 15.50 | 20.71 | 2.13 | 10.12 | 650,807 | -10.68 | -68.90% |
3 Years | 15.50 | 20.71 | 2.13 | 10.12 | 650,807 | -10.68 | -68.90% |
5 Years | 15.50 | 20.71 | 2.13 | 10.12 | 650,807 | -10.68 | -68.90% |
Sagiment Biosciences Description
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. |